Literature DB >> 2441520

Studies on the glycosylation of flavivirus E proteins and the role of carbohydrate in antigenic structure.

G Winkler, F X Heinz, C Kunz.   

Abstract

The glycosylation pattern of several flavivirus E proteins as well as the role of carbohydrate in biological functions and the antigenic structure of tick-borne encephalitis (TBE) virus were investigated by the use of specific endoglycosidases. Endoglycosidase F digestion revealed the presence of a single asparagine-linked oligosaccharide side chain in TBE virus (Western and Far Eastern subtype), Louping III virus, Murray Valley encephalitis virus, and Rocio virus. Consistent with published sequence data, the E protein of West Nile virus apparently is not glycosylated at all. Evidence derived from digestion experiments using endoglycosidase H indicates that the tick-borne viruses contain high-mannose type N-linked oligosaccharide side chains, whereas that of the mosquito-borne Murray Valley encephalitis virus and Rocio virus is endoglycosidase H resistant. Complete deglycosylation of TBE virus by endoglycosidase F did not impair infectivity and HA activity. Carbohydrate does not seem to play a major role in the antigenic structure of the TBE virus glycoprotein since the reactivity of the native virus and the deglycosylated virus was identical when analyzed with monoclonal as well as polyclonal immune sera.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2441520     DOI: 10.1016/0042-6822(87)90460-0

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  24 in total

1.  Intracellular assembly and secretion of recombinant subviral particles from tick-borne encephalitis virus.

Authors:  Ivo C Lorenz; Jürgen Kartenbeck; Anna Mezzacasa; Steven L Allison; Franz X Heinz; Ari Helenius
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

2.  Two distinct size classes of immature and mature subviral particles from tick-borne encephalitis virus.

Authors:  Steven L Allison; Yizhi J Tao; Gabriel O'Riordain; Christian W Mandl; Stephen C Harrison; Franz X Heinz
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

Review 3.  Carbohydrate analysis of glycoproteins. A review.

Authors:  K B Lee; D Loganathan; Z M Merchant; R J Linhardt
Journal:  Appl Biochem Biotechnol       Date:  1990-01       Impact factor: 2.926

Review 4.  Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity.

Authors:  Laura A VanBlargan; Leslie Goo; Theodore C Pierson
Journal:  Microbiol Mol Biol Rev       Date:  2016-10-26       Impact factor: 11.056

5.  In vitro processing of dengue virus structural proteins: cleavage of the pre-membrane protein.

Authors:  L Markoff
Journal:  J Virol       Date:  1989-08       Impact factor: 5.103

Review 6.  Flavivirus Envelope Protein Glycosylation: Impacts on Viral Infection and Pathogenesis.

Authors:  Derek L Carbaugh; Helen M Lazear
Journal:  J Virol       Date:  2020-05-18       Impact factor: 5.103

7.  Recombinant subviral particles from tick-borne encephalitis virus are fusogenic and provide a model system for studying flavivirus envelope glycoprotein functions.

Authors:  J Schalich; S L Allison; K Stiasny; C W Mandl; C Kunz; F X Heinz
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

8.  Inhibition of type 5 adenovirus infectivity by periodate oxidation.

Authors:  G Ogier; Y Michal; V Thomas; G Quash; J D Rodwell
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

9.  Chimeric tick-borne encephalitis and dengue type 4 viruses: effects of mutations on neurovirulence in mice.

Authors:  A G Pletnev; M Bray; C J Lai
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

10.  The Murray Valley encephalitis virus prM protein confers acid resistance to virus particles and alters the expression of epitopes within the R2 domain of E glycoprotein.

Authors:  F Guirakhoo; R A Bolin; J T Roehrig
Journal:  Virology       Date:  1992-12       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.